ReBio Pharma

ReBio Pharma is a clinical-stage biotechnology company specializing in the development of long-acting injectable formulations using its proprietary SISU (Sustained In-Situ) drug delivery platform. The company's technology enables the controlled release of established and novel therapeutics, aiming to improve patient compliance and clinical outcomes in chronic conditions. Its lead program, RBP-001, is a long-acting formulation of latanoprost for the treatment of glaucoma and ocular hypertension. ReBio Pharma operates with a focus on ophthalmology but explores applications in other therapeutic areas requiring sustained drug delivery.